Keyword: Alexion Pharmaceuticals
BridgeBio's new spinout launches with a synthetic enzyme replacement from Alexion for an ultrarare genetic disease that causes seizures in infants.
David Thompson has left Azure Biotech to join Inozyme Pharma as chief scientific officer as the company transitions to the clinical stage.
The takeover furthers Alexion’s pipeline rebuild by giving it control of WTX101, a phase 3 treatment for the rare genetic disorder Wilson disease.
Abeona is tapping industry vet Carsten Thiel, Ph.D., for its new leader in the cell and gene therapy space, with an eye to the commercial future.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics.
The rejig sees Alexion scrapping deals with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma as it seeks to focus its R&D.
It’s not been a great six months for the leadership of Alexion as a sales scandal has forced a series of major changes at the top of the organization; one of these was Martin Mackay, who will “retire” this year, and will now be replaced by John Orloff, M.D.
Alexion Pharmaceuticals is set to lay off 7% of its staff and scrap some R&D programs to restructure its business following a tricky period.